Group items tagged

PHOENIX UK and the British Heart Foundation has joined hands for a charity partnership to continue the ongoing commitment of improving heart health across the UK. The PHOENIX team have set the donation goal of £20,000 by June 2023 and are set to take on a range of exciting challenges over the course of the next year, such as a Tough Mudder and the Yorkshire Three Peaks challenge, all in a bid to raise funds for the heart health charity. Nigel Swift, Managing Director of Rowlands, PHOENIX UK's largest community pharmacy member organisation, commented: "We are thrilled to be partnering with The British Heart Foundation. Its lifesaving research perfectly aligns with our mission across PHOENIX UK - to enable more people to live happy and healthy lives - and so we look forward to raising vital funds and supporting the excellent work of the charity." Hayley Gough, Community Relationship Manager at The British Heart Foundation, added, "It's fantastic to see the team at PHOENIX UK commit to raising so much money for The British Heart Foundation. We can't wait to see all that they achieve and are so grateful for their fundraising efforts."

british vlogger,british beauty blogger,british youtubers,uk youtuber,xameliax,british lifestyle blogger,does plump it lip plumper really work?,does plump it lip plumper work?,how to get big lips naturally,plump it lip plumper review,plump it volumising lip plumper review,how to get big lips fast,how to get bigger lips fast,how to get bigger lips without fillers,plump it test on thin lips,how to get bigger lips at home,where to buy plump it lip plumper

HayMax, maker of the famous organic drug-free allergen barrier balm has been awarded the 'British Made Award' for Best British Allergy Product 2022. The award celebrates businesses that work tirelessly to make their region one of the most diverse and dynamic the UK has to offer. HayMax MD and creator Max Wiseberg comments: "This award means a great deal to us. We've always been proud that our products have been manufactured in the UK. We are passionate about reducing the cost to the environment so being British-made means we keep the miles down and reduce our carbon footprint." HayMax balms are manufactured in the UK. It buys local to reduce the cost to the environment, even if it means it costs a bit more. HayMax's current pots are now made in the UK, which has been great for reducing their carbon footprint. Its tins come from London. The new pots can be recycled and re-used. The brand has now switched to using sugar cane to make its pots and has also reduced the amount of material used in the pots by just over 54%. And they have switched from the plastic labels to paper labels.

British drugmaker AstraZeneca says it's confident that its new version of COVID-19 antibody treatment could protect immunocompromised patients against all known virus variants. Laboratory studies show the antibody, called AZD3152, neutralises all known variants of COVID-19 and AstraZeneca has support from regulators to make the treatment available by the end of this year, the company's vaccines head Iskra Reic said on Tuesday (April 18). AstraZeneca plans, pending more positive data and regulatory approval, to make the antibody available by the end of 2023. These types of therapies are most needed for people with compromised immune systems, either because of underlying conditions or because they are undergoing immune suppressing treatments. They account for nearly 2% of the global population. AstraZeneca's AZD3152, it new COVID-19 antibody, was acquired through a $157 million deal last year with British biotech start-up RQ Bio. The British drugmaker will likely make future investments like its current partnerships with RQ Bio but did not have any deals to announce, said Reic, a long-time AstraZeneca executive who has led the company's vaccines and immune therapies unit since it was formed in late 2021, during the pandemic.

Wockhardt UK managing director Ravindra Limaye has been chosen for honorary British awards given to foreign nationals. Limaye gets the Order of the British Empire (OBE) honour for his contribution to health, particularly during the Covid-19 pandemic. The honours were announced on Thursday (13). Limaye has been the chief executive of the UK arm of the Mumbai-based pharma and biotech company Wockhardt since 2019. He previously worked for another Indian pharma company Biocon, overseeing its global commercial operations. He led the company's entry into global biosimilar markets and spearheaded its operations in the US.

After a month of intense talks, the British government and unions representing consultant doctors in England have reached an agreement, potentially ending six months of disruptive strike action. The Department of Health and Social Care (DHSC) has put forward an offer to reform the pay structure for senior doctors from January 2024, reducing the number of pay points and the time it takes to reach the top. As part of this offer, consultants will also be entitled to enhanced shared parental leave, bringing them in line with other NHS staff. New arrangements will ensure a clearer link between pay progression and evidence of skills, competencies and experience, the DHSC said. The British Medical Association (BMA) and Hospital Consultants and Specialists Association (HCSA) agreed to put the offer to their members for a vote in the coming weeks, with no further strike action to be called during that time.

A community pharmacist, Viral Doshi was honoured with the British Citizen Award (BCA) on Thursday (26 January) at the Palace of Westminster for transforming his community centre into vaccination hub during Covid-19 pandemic. Viral was presented with his Medal of Honour by Liam Sargeant, Senior Company Communications Manager, from supporters P&G and TV presenter and Patron of the BCA, Nick Knowles, who hosted the event. At the height of the pandemic, Viral obtained approval to transform his community centre into a vaccination hub. Located in the heart of a multi-ethnic population, with social deprivation, surrounded by wards experiencing high rates of Covid-19. His determination to increase uptake and reduce vaccination hesitancy, led to 80,000 vaccinations being administered, the overall highest vaccination uptake in North West London. Viral is a passionate advocate for the role that GP practices and community pharmacies can play in supporting the health agenda. His objective, to provide better choice and access for the community have been fully met and appreciated by patients. His initiatives led to a dramatic increase in the clinical skills, knowledge and services offered by local community pharmacies around a variety of health topics. This enabled pharmacies to adopt a holistic health approach to working with their communities.

The finest range of cheese and charcuterie gifts online in the UK. Explore our Choose the perfect hamper from a range of high-quality artisan brands. The perfect gift for Christmas, Birthdays or just to say thankyou.

Red roses, chocolates, dinner at a high-end restaurant, and a ring are all old-school stuff, now you need something special to impress the love of your life. What's that? Best of British Charcuterie Platter has the best British cured meat, artisan cheese, and premium accompaniments.

The High Court has dismissed the British Generic Manufacturers Association (BGMA)'s claim on being excluded from ongoing negotiations between the government and industry to agree a new Voluntary Scheme for medicine pricing and access (VPAS). The association had sought a judicial review of the Department of Health and Social Care's (DHSC) decision to negotiate a new Voluntary Scheme for branded medicines with the Association of the British Pharmaceutical Industry (ABPI) in April. Commenting on the result of the case, Richard Torbett, Chief Executive of the ABPI said: "For over 60 years the ABPI has acted as the representative industry body for negotiations on the Voluntary Scheme for branded medicines - a responsibility we take extremely seriously - and one which has been reaffirmed by today's judgment. "While we were disappointed that the BGMA decided to take this action - we recognise their decision was driven by the extreme challenge placed on all parts of the industry from the surge in the branded medicine payment rates. "The solution to these problems must be a completely new and sustainable approach to medicines provision in the UK which rapidly brings industry revenue payments in line with comparator countries to unlock investment and growth."

The British Generic Manufacturers Association (BGMA) has warned of the significant implications for future supply as a result of the crippling VPAS rate. The warning comes after the association's judicial review into the Government's decision to bar it from being a full part of the negotiations for the next five-year VPAS period was dismissed. The voluntary scheme for branded medicines pricing and access (VPAS) is an agreement between the Department of Health and Social Care (DHSC), NHS England and The Association of the British Pharmaceutical Industry (ABPI). The scheme aims to limit increases in spending on branded medicines to no more than 2% per year via a rebate system which is charged on companies' sales revenues. Two years ago, the rate was 5.1%, but in 2023 it has soared to 26.5%. All biosimilars and a proportion of the generics market falls into the scheme.

The British Generic Manufacturers Association (BGMA) has sought a judicial review of the Department of Health and Social Care's (DHSC) decision to negotiate a new Voluntary Scheme for branded medicines with the Association of the British Pharmaceutical Industry (ABPI). Mark Samuels, Chief Executive of BGMA said: "The Government has decided not to involve the trade body representing these medicine suppliers in its negotiations on the voluntary scheme for branded medicine pricing (VPAS). "We are deeply concerned by this decision. It has left us no choice but to take legal action." "While not all generic drugs fall within VPAS, four out of ten products in the current scheme are branded generics or biosimilars. As the representative trade body for both generic and biosimilar UK manufacturers, we must play a full part in the VPAS negotiations for the next period of the scheme from 2024 to 2028." "The VPAS tax has risen five-fold in under two years, an unprecedented tax increase. Yet our sector currently has no input into the negotiations on future schemes or rates; this is untenable as any decisions made on VPAS could significantly define the future of our sector in the UK and its ability to supply the NHS. The association had raised its full participation in the negotiations with the Government last November.

Women in the UK will be able to purchase Gina 10 mg vaginal tablets without prescription from September from their local pharmacies, announced the Medicines and Healthcare products Regulatory Agency (MHRA). The Hormone Replacement Therapy (HRT) product, Gina 10 microgram vaginal tablets (containing estradiol) are used for the treatment of vaginal symptoms such as dryness, soreness, itching, burning and uncomfortable sex caused by oestrogen deficiency in postmenopausal women aged 50 years and above who have not had a period for at least one year. The decision to reclassify these vaginal tablets follows a safety review by the MHRA, independent advice from the Commission on Human Medicines (CHM), and a public consultation. The UK regulator sought views from patients, pharmacists, prescribers and a wide range of stakeholders including the Royal College of Obstetricians & Gynaecologists, the Faculty of Sexual & Reproductive Healthcare, the British Pharmacopoeia Commission and the British Menopause Society.

Former chancellor Rishi Sunak on Monday (October 24) won the battle for leader of Britain's Conservative party and will become the country's first prime minister of colour. Penny Mordaunt, the last rival left after Boris Johnson dramatically pulled out, failed to secure the necessary 100 nominations from her fellow MPs. "Rishi Sunak is therefore elected as leader of the Conservative party," senior backbencher Graham Brady said, as Mordaunt pledged her "full support" for Sunak. Sunak's triumph came after Johnson's decision late Sunday to abandon his political comeback bid. Just weeks after he lost out to Liz Truss to lead the ruling Tories, Sunak therefore pulled off a stunning reversal in fortunes. The contest, triggered by outgoing leader Truss's resignation on Thursday, had required candidates to secure the support of at least 100 Conservative MPs by 2:00 pm (1300 GMT) on Monday.

The British Generic Manufacturers Association (BGMA) has published a positioning paper which sets out the objectives that need to be delivered through the next Voluntary Pricing and Access Scheme (VPAS) on Thursday (15 June). The paper details how a financially sustainable VPAS can support widened medicines access to patients. VPAS is an agreement between the Department of Health and Social Care (DHSC), NHS England and The Association of the British Pharmaceutical Industry (ABPI). The scheme aims to limit increases in spending on branded medicines to no more than 2% per year via a rebate system which is charged on companies' sales revenues. Two years ago, the rate was 5.1% but for 2023 it has soared to 26.5%. Last year, the association had raised concerns over the rise in the VPAS rate for 2023 to 26.5 per cent. "The rocketing rate is in large part due to the growth in spend in on-patent medicines since 2019. Looking at the four completed years of the current VPAS scheme, data shows that the average annual growth rate for on-patent medicine sales value from 2019-22 was 18% compared to just 2% for off-patent products," said the association.

British health agencies have secured funding to develop a standardised approach to test the performance of vaccines being used or in development against monkeypox, days after the World Health Organization labelled the growing outbreak a global health emergency. The Coalition for Epidemic Preparedness Innovations (CEPI) said it would give up to $375,000 to the Medicines and Healthcare products Regulatory Agency (MHRA) and Health Security Agency (UKHSA) to develop standard tools to assess the strength and duration of immune responses generated by current vaccines, and for tests used to detect monkeypox antibody levels. Apart from administration fees, these tools will be made freely available to the global scientific community, paving the way for a common standardised assessment between countries documenting vaccine performance against monkeypox, CEPI said. Until this year, the viral disease has rarely spread outside Africa where it is endemic. But reports of a handful of cases in Britain in early May signalled that the outbreak had moved into Europe. So far, there have been more than 16,000 confirmed cases of monkeypox in more than 75 countries.

The Royal Pharmaceutical Society (RPS) has appointed Neville Carter as its new chief education and membership officer. Neville joins RPS from the Royal Society of Medicine (RSM) where he is currently director of engagement, leading a team of over 60 and responsible for creating a combined directorate accountable for education, membership, philanthropy, and business development. He has, in particular, led on the development of a digital education strategy and launched professional development training programmes for members. Prior to joining the RSM, Neville worked as director of product and sales at the British Medical Association with responsibility for membership growth, supporting corporate transformation and developing and managing member benefits and relationships with third-party providers to support revenue growth. He also has senior manager experience at the RAC and at British Airways. Commenting on the appointment, Paul Bennett, RPS CEO, said: "I'm delighted that Neville will be joining our Executive team. He brings a wealth of relevant experience and this, in combination with a strong existing education and membership team at RPS and a clear ambition to strengthen the relevant functions further, will enable the organisation to deliver a dynamic offering for our members.

The British Generic Manufacturers Association (BGMA) has raised concerns over the rise in the VPAS rate for 2023 to 26.5 per cent. The Department of Health Social Care (DHSC) today announced that the 2019 voluntary scheme payment percentage for 2023 will be 26.5%. The 2019 voluntary scheme for branded medicines pricing and access is an agreement between the Department of Health and Social Care, NHS England and the Association of the British Pharmaceutical Industry. BGMA believes that the high VPAS tax for 2023 risks more medicines shortages, rising prices for the NHS via reduced competition, and new medicine launches to the UK being deferred. Mark Samuels, Chief Executive of BGMA, said: "Raising the VPAS tax to 26.5% will damage the UK's medicines supply because it will make some products lossmaking. It is more than a five-fold tax increase from 2021, and no industry can cope with this unpredictable and exceptional tax volatility.

Orphan Drug development specialist TMC Pharma has appointed Gordon Cameron to its board as a non-executive director. Mr Cameron has 25 years' board-level experience in biotech and pharmaceutical services sectors. He started his career with EY, then spent several years in investment banking at Rothschild before becoming CFO, and then CEO, of international vaccine company Acambis. For the past 15 years, Mr Cameron has been CFO of Quotient Sciences, an international Contract Development and Manufacturing Organisation and Clinical Research Organisation. In 2004, he was awarded the Officer of the Order of the British Empire for services to the British biotechnology industry. Julie Matthews, chief executive officer of TMC Pharma, said that the new appointment would "enhance our strategic capability and tactical execution as we consolidate our position as a global leader in the Orphan Drug development market."

Shabbir Jafferali, owner of Wilmshurst Pharmacy in Lancing, is one of 28 remarkable individuals who will be recognised with the prestigious British Citizen Award (BCA) at the Palace of Westminster on Thursday, January 18. The BCA, in partnership with One Stop, recognises exceptional people around the UK who are making a difference in their communities. Sussex Express, which first broke the news, stated that Shabbir has been working as a community pharmacist for over 40 years, providing not only health care, but a listening ear and selfless community care. He treats everyone who use his pharmacy with sensitivity and care, and takes the time to know the names and ailments of his customers as well as their personal circumstances.

The British Generic Manufacturers Association (BGMA) on Monday alerted the Health and Social Care Committee that medicines shortages have increased and are "around double what they were a year ago." BGMA chief executive Mark Samuels told the committee that they have been highlighting the medicine shortage risk to ministers since July 2021 and the association is "very concerned" about the current situation. "We've been monitoring it for several years now, and as you saw in the written evidence, shortages have increased. They're around double what they were a year ago. We have them at 101 shortages in February this year," said Samuels. Dr Rick Greville, director of distribution and supply at the Association of the British Pharmaceutical Industry (ABPI), highlighted that the problem of drug shortages in the UK is a "long-standing issue" and the scarcity of certain medications "continues to be challenging".